当社グループは 3,000 以上の世界的なカンファレンスシリーズ 米国、ヨーロッパ、世界中で毎年イベントが開催されます。 1,000 のより科学的な学会からの支援を受けたアジア および 700 以上の オープン アクセスを発行ジャーナルには 50,000 人以上の著名人が掲載されており、科学者が編集委員として名高い
。オープンアクセスジャーナルはより多くの読者と引用を獲得
700 ジャーナル と 15,000,000 人の読者 各ジャーナルは 25,000 人以上の読者を獲得
Jian Zhang and De-Yan Cao
Background: We aimed to investigate the clinical significance and biological roles of ARHGAP11A in lung adenocarcinoma (LUAD). Methods: We firstly analyzed the expression level of ARHGAP11A in LUAD based on TCGA. Next, quantitative reverse transcription PCR (qRT-PCR) was performed to examine the expression level of ARHGAP11A in LUAD cell lines (A549, and Calu-3). After ARHGAP11A knockdown in A549 cells, cell counting kit-8 (CCK-8) and trans well assays were used to measure the proliferation and migration ability of A549 cells with or without ARHGAP11A silence. Western blotting was utilized to identify the underlying pathway through which ARHGAP11A silencing mediates biological roles in LUAD. Results: ARHGAP11A was significantly over-expressed in LUAD tissues. Patients in the high ARHGAP11A expression subgroup experienced worse overall survival compared to the low expression subgroup. Univariate and multivariate analysis exhibited that ARHGAP11A was an independent prognostic predictor for LUAD. After ARHGAP11A silencing in A549 cells, cell proliferation rate, invasive and migratory capacity were observed to be inhibited. Remarkably, western blot results exhibited that reduction of ARHGAP11A remarkably inhibited the expression of ROCK, pLIMK2, and pCofilin in A549 cells. Conclusion: Increased ARHGAP11A expression could regulate LUAD cell proliferation and metastasis, and identified it as a poor prognostic biomarker in LUAD.